14 recruiting, 5 not yet recruiting, 1 active not recruiting, 1 terminated. 21 Phase 2, 3 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 21 | Recruiting 14, Not yet recruiting 5, Active not recruiting 1, Terminated 1 |
| Phase 1 | 3 | Recruiting 2, Terminated 1 |
| Phase 3 | 2 | Active not recruiting 1, Recruiting 1 |
Follow XL092: new trials by email Literature Review of XL092 trials Research Report on XL092
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zanzalintinib in Unresectable and Progressive MPGGs Zanzalintinib - Pheochromocytoma, Paraganglioma | Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 14 | 2027-01-09 | 2026-07-20 |
| Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy Biospecimen Collection, Bone Scan, C. butyricum CBM 588 Probiotic Strain Capsule Formulation MO-03 - Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8 | Phase 2 | Not yet recruiting | City of Hope Medical Center | 34 | 2026-11-28 | 2026-05-11 |
| Zanzalintinib Efficacy Post Pluvicto® in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Zanzalintinib - mCRPC (Metastatic Castration-resistant Prostate Cancer) | Phase 2 | Not yet recruiting | Stuthi Perimbeti | 30 | 2026-11-01 | 2026-11-04 |
| Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer Cemiplimab, Zanzalintinib - Anaplastic Thyroid Cancer | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 12 | 2026-10-29 | 2026-11-17 |
| A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma Zanzalintinib - Metastatic Olfactory Neuroblastoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 16 | 2026-10-01 | 2026-11-10 |
| H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC) XL092, Pembrolizumab - Oral Cavity Squamous Cell Carcinoma, Head and Neck Cancer | Phase 2 | Not yet recruiting | UNC Lineberger Comprehensive Cancer Center | 26 | 2026-09-01 | 2026-08-31 |
| Zanzalintinib in Men With Aggressive Variant Prostate Cancer Zanzalintinib - Aggressive Variant Prostate Carcinoma | Phase 2 | Recruiting | Deepak Kilari | 30 | 2026-08-19 | 2026-08-28 |
| Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases Zanzalintinib, Investigator Choice of Bone Strengthening Agents (BSA), Non-Investigational Radiation Therapy (RT) - Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma | Phase 2 | Recruiting | Kelly Fitzgerald, MD | 20 | 2026-06-10 | 2026-07-27 |
| A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma Zanzalintinib - Meningioma | Phase 2 | Recruiting | Exelixis | 100 | 2026-05-21 | 2026-10-28 |
| Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma Angiogram, Biopsy Procedure, Biospecimen Collection - Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | OHSU Knight Cancer Institute | 40 | 2026-04-02 | 2026-04-06 |
| Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Advanced Hepatocellular Carcinoma, Cirrhosis | Phase 1 / Phase 2 | Recruiting | Devalingam Mahalingam | 59 | 2026-03-30 | 2026-10-23 |
| Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC XL092, Nivolumab - Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | Phase 2 | Recruiting | Karie Runcie | 70 | 2026-03-13 | 2026-09-22 |
| A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE) Zanzalintinib - Bone Sarcomas | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 70 | 2025-12-05 | 2026-09-25 |
| Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis Zanzalintinib, Nivolumab - Locally Advanced Renal Cell Carcinoma | Phase 2 | Recruiting | Qian Qin | 69 | 2025-10-30 | 2026-09-04 |
| Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors Zanzalintinib, Everolimus - Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET) | Phase 2 / Phase 3 | Recruiting | Exelixis | 440 | 2025-07-21 | 2026-10-30 |
| Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03) Belzutifan, Zanzalintinib - Renal Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 140 | 2025-07-20 | 2026-10-27 |
| XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Locally Advanced Differentiated Thyroid Gland Carcinoma, Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma | Phase 2 | Recruiting | Jochen Lorch | 33 | 2025-06-06 | 2026-06-26 |
| XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer XL092 - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | University of Utah | 32 | 2024-12-09 | 2026-06-29 |
| XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma Biospecimen Collection, Computed Tomography, Echocardiography - Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma | Phase 2 | Recruiting | Northwestern University | 73 | 2024-09-19 | 2026-10-13 |
| Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Zanzalintinib, Zanzalintinib-matched Placebo, Pembrolizumab - Head and Neck Squamous Cell Carcinoma | Phase 2 / Phase 3 | Active not recruiting | Exelixis | 600 | 2024-06-07 | 2025-08-17 |
Showing 20 of 21. Sign in to see all of them.
Carcinoma, Renal Cell (4) · Bone Neoplasms (2) · Carcinoma, Hepatocellular (2) · Clear-cell metastatic renal cell carcinoma (2) · Neoplasm Metastasis (2) · Squamous Cell Carcinoma of Head and Neck (2) · Adenocarcinoma, Follicular (1) · Adenoma, Islet Cell (1) · Brain Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Esthesioneuroblastoma, Olfactory (1) · Fibrosis (1) · Head and Neck Neoplasms (1) · Leiomyosarcoma (1) · Meningioma (1)
Exelixis (3) · M.D. Anderson Cancer Center (3) · City of Hope Medical Center (1) · Dana-Farber Cancer Institute (1) · Deepak Kilari (1) · Devalingam Mahalingam (1) · Hoffmann-La Roche (1) · Jochen Lorch (1) · Karie Runcie (1) · Kelly Fitzgerald, MD (1) · Merck Sharp & Dohme LLC (1) · Northwestern University (1) · OHSU Knight Cancer Institute (1) · Qian Qin (1) · Stuthi Perimbeti (1)
United States (20) · France (4) · South Korea (4) · Spain (4) · United Kingdom (4) · Australia (3) · Israel (3) · Poland (3) · Austria (2) · Belgium (2) · Brazil (2) · Chile (2) · Germany (2) · Italy (2) · Mexico (2)
Adel Kardosh (1) · Deepak Kilari, MD (1) · Devalingam Mahalingam (1) · Jochen H Lorch (1) · John Livingston, MD (1) · Karie Runcie, MD (1) · Kelly Fitzgerald, MD (1) · Kimbery Perez, MD (1) · Luana Sousa, MD (1) · Pedro Hermida de Viveiros, MD (1) · Qian Qin, MD (1) · Sarah Hamidi, MD (1) · Siddharth Sheth, MD (1)
P30CA060553 (3), 2017 (1), 2025 (1), P30CA033572 (1)